Two Sigma Securities’s Black Diamond Therapeutics BDTX Stock Holding History

Two Sigma Securities’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.5K	Sell	16,663 -23,875	-59%	-$56.8K	﹤0.01%	1304
2025 Q4	$98.5K	Buy	40,538 +25,922	+177%	+$91.8K	0.01%	980
2025 Q3	$55.4K	Buy	14,616 +1,512	+12%	+$4.42K	0.01%	973
2025 Q2	$32.5K	Buy	+13,104	New	+$25.3K	﹤0.01%	1146

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Securities's BDTX Position: Q1 2026 in Review

Two Sigma Securities reduced its Black Diamond Therapeutics (BDTX) stake by 59% in Q1 2026, selling an estimated $56.8K and leaving 16,663 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Two Sigma Securities first reported a position in BDTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $98.5K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Two Sigma Securities held 16,663 shares of Black Diamond Therapeutics worth $35.5K as of Q1 2026.
Two Sigma Securities sold 23,875 Black Diamond Therapeutics shares in Q1 2026, an estimated $56.8K.
Black Diamond Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1304 holding.
Two Sigma Securities first reported a position in Black Diamond Therapeutics in Q2 2025 and has held it in 4 quarters since.
Two Sigma Securities's Black Diamond Therapeutics position peaked at $98.5K in Q4 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.